AR060648A1 - Formas cristalinas de un compuesto de dimetilfenilo carbamoil etil piperidina - Google Patents

Formas cristalinas de un compuesto de dimetilfenilo carbamoil etil piperidina

Info

Publication number
AR060648A1
AR060648A1 ARP070101778A ARP070101778A AR060648A1 AR 060648 A1 AR060648 A1 AR 060648A1 AR P070101778 A ARP070101778 A AR P070101778A AR P070101778 A ARP070101778 A AR P070101778A AR 060648 A1 AR060648 A1 AR 060648A1
Authority
AR
Argentina
Prior art keywords
carbamoil
etil
piperidine
crystal forms
dimethylene compound
Prior art date
Application number
ARP070101778A
Other languages
English (en)
Spanish (es)
Inventor
Miroslav Rapta
Lisa Williams
Jennifer Bolton
Robert Chao
Richard D Wilson
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR060648A1 publication Critical patent/AR060648A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ARP070101778A 2006-04-25 2007-04-24 Formas cristalinas de un compuesto de dimetilfenilo carbamoil etil piperidina AR060648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79470906P 2006-04-25 2006-04-25

Publications (1)

Publication Number Publication Date
AR060648A1 true AR060648A1 (es) 2008-07-02

Family

ID=38556280

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101778A AR060648A1 (es) 2006-04-25 2007-04-24 Formas cristalinas de un compuesto de dimetilfenilo carbamoil etil piperidina

Country Status (10)

Country Link
US (2) US7880010B2 (enExample)
EP (1) EP2010490B1 (enExample)
JP (1) JP2009535340A (enExample)
CN (1) CN101426765A (enExample)
AR (1) AR060648A1 (enExample)
AT (1) ATE520660T1 (enExample)
CA (1) CA2650631A1 (enExample)
PE (1) PE20080195A1 (enExample)
TW (1) TW200811104A (enExample)
WO (1) WO2007127297A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
WO2004087243A1 (ja) 2003-03-27 2004-10-14 Bioactis Limited 鼻腔用粉末薬剤施薬装置
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
US20090216010A1 (en) * 2008-02-22 2009-08-27 Wei-Hong Tseng Crystalline carbapenem compound and produced method thereof
CA2758353C (en) * 2009-04-14 2017-06-06 Dean David Edney Process for the preparation of a biphenyl-2-ylcarbamic acid ester
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITION WITH IMPROVED PHARMACOKINETICS
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
JP5877277B2 (ja) * 2013-04-26 2016-03-02 富士フイルム株式会社 撮像装置及び画像表示方法
CN107108502A (zh) * 2015-05-14 2017-08-29 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1622875B1 (en) * 2003-05-08 2009-12-02 Theravance, Inc. Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
US7558576B2 (en) * 2005-03-29 2009-07-07 Qualcomm Incorporated Employing frequency offset to compensate for Doppler shift
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
PE20080195A1 (es) 2008-04-04
EP2010490A2 (en) 2009-01-07
WO2007127297A2 (en) 2007-11-08
ATE520660T1 (de) 2011-09-15
US7880010B2 (en) 2011-02-01
US20110086881A1 (en) 2011-04-14
WO2007127297A3 (en) 2007-12-21
TW200811104A (en) 2008-03-01
JP2009535340A (ja) 2009-10-01
CN101426765A (zh) 2009-05-06
CA2650631A1 (en) 2007-11-08
EP2010490B1 (en) 2011-08-17
US20070249674A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
AR051003A1 (es) Forma cristalina de un compuesto bifenilo
AR106744A2 (es) Formas cristalinas de un compuesto de bifenilo
WO2007127297A3 (en) Crystalline forms of a dimethylphenyl compound
PE20110810A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
EA201390481A1 (ru) Кристаллические оксалатные соли диамидного соединения
AR104288A2 (es) Forma cristalina i de la sal del ácido succínico de 1-[2-(2-cloro-4-[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil-5-metoxifenilcarbamoil)etil]piperidin-4-il éster del ácido bifenil-2-ilcarbámico, composiciones, combinaciones y procedimiento para su preparación
AR061926A1 (es) Compuestos de piperidina, utiles como inhibidores de la proteina de transfe-rencia de esteres de colesterol, composicion farmaceutica y uso
SG10201407913UA (en) Crystalline freebase forms of a biphenyl compound
ITMI20050912A1 (it) Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
JO3142B1 (ar) طريقة تحضير 5-ثنائي فينيل -4-أمينو-2-ميثيل بينتانويك أسيد
ATE455110T1 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DK2021336T3 (da) 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
BR112013000877A2 (pt) processo para a preparação de um ácido bifenil-2-il carbâmico
CO6361988A2 (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
BRPI0909560A2 (pt) processo de preparação de derivaods de ácido 1-(2-halo-bifenil-4-il)-ciclopropano carboxílico
EA200900985A1 (ru) Способ получения оптически чистого омепразола
CU20120087A7 (es) Procedimiento de síntesis y forma cristalina del hidrocloruro de 4-(3-(cis-hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida así como las composiciones farmacéuticas que la contienen
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
CY1112979T1 (el) Διαδικασια για την παρασκευη της ενωσης (s)-1-αλκυλ-2',6'-πιπεκολοξυλιδιδιου
CY1117075T1 (el) Κρυσταλλικη ελευθερη βαση σε μορφη μιας διφαινυλικης ενωσης
ECSP099383A (es) Derivado piperidínico utilizado para tratar enfermedades mediadas por el receptor 5 de quimiocina
ATE546451T1 (de) Cyclopropancarbonsäureester von acyclovir
HK1186729A (en) Crystalline oxalate salts of a diamide compound
TH110694A (th) เตตระไฮโดรซินโนลีนในฐานะตัวยับยั้ง 11 เบต้า hsd1 สำหรับโรคเบาหวาน

Legal Events

Date Code Title Description
FB Suspension of granting procedure